Allogene Therapeutics Inc Dividends
The next dividend date for Allogene Therapeutics Inc has not yet been scheduled.
What is a Dividend Date
When we talk about a dividend date, we’re referring specifically to the ex-dividend date.
This is the date on which all stockholders will earn a dividend. Technically, a person needs to be the owner of a share of stock as of the night before the ex-dividend date in order to earn the dividend.
The ex-dividend date is different than the date when the dividend is issued. Although you earn a dividend on the ex-dividend date, that dividend is typically not disbursed to your account until several weeks later.
Most brokerages will automatically credit the dividend to your account once it’s issued.
Historical Dividends for Allogene Therapeutics Inc (ALLO)
More About Allogene Therapeutics Inc
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Owning Allogene Therapeutics Inc Stock on the Dividend Date
If you own Allogene Therapeutics Inc stock on the ex-dividend date, then you earn the associated dividend.
Theoretically, the price of Allogene Therapeutics Inc stock should go down by the amount of the dividend (in addition to any other pressures that market forces have on the price of Allogene Therapeutics Inc stock).
Therefore, it is typically not expected that there is any incremental profit to be gained from buying Allogene Therapeutics Inc stock right before the ex-dividend date and then selling it immediately after. It’s not like you get the Allogene Therapeutics Inc dividend payout for free just by doing that since there is typically an equivalent commensurate drop in the stock price.
Learning More Allogene Therapeutics Inc Dividends
You can contact us any time if you would like to ask questions about Allogene Therapeutics Inc dividends or anything else related to the stock market.